- Barclays Capital Global Healthcare Conference on March 10 -
- 29th Annual Cowen and Company Healthcare Conference on March 17 -
SAN DIEGO, March 5 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated
(Nasdaq: GPRO) announced today that the Company will present at the Barclays
Capital Global Healthcare Conference in Miami on March 10, 2009 at
approximately 2:30 p.m. Eastern time, and at the 29th Annual Cowen and Company
Healthcare Conference in Boston on March 17, 2009 at approximately 11 a.m.
Eastern time. The presentations are scheduled to be webcast live and may be
accessed through a link on the investors section of Gen-Probe's website at
www.gen-probe.com. The webcasts will be available for 30 days following the
events.
About Gen-Probe
Gen-Probe Incorporated is a global leader in the development, manufacture
and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs)
that are used primarily to diagnose human diseases and screen donated human
blood. Gen-Probe has more than 25 years of NAT expertise, and received the
2004 National Medal of Technology, America's highest honor for technological
innovation, for developing NAT assays for blood screening. Gen-Probe is
headquartered in San Diego and employs approximately 1,000 people. For more
information, go to www.gen-probe.com.
Caution Regarding Forward-Looking Statements
Any statements in this press release about our expectations, beliefs,
plans, objectives, assumptions, or future events or performance are not
historical facts and are forward-looking statements. Forward-looking
statements are not guarantees of performance. They involve known and unknown
risks, uncertainties and assumptions that may cause actual results, levels of
activity, performance or achievements to differ materially from those
expressed or implied. For information about risks and uncertainties we face
and a discussion of our financial statements and footnotes, see documents we
have filed with the SEC, including the Form 10-K for the year ended December
31, 2008, and all subsequent periodic filings made with the SEC. We assume no
obligation and expressly disclaim any duty to update any forward-looking
statement to reflect events or circumstances after the date of this press
release or to reflect the occurrence of unanticipated events.
Contact:
Paula Izidoro
Investor Relations
858-410-8904
SOURCE Gen-Probe Incorporated
03/05/2009
CONTACT: Paula Izidoro, Investor Relations of Gen-Probe Incorporated,
+1-858-410-8904
/Web Site: http://www.gen-probe.com/
(GPRO)
|